Showing results (611-620 of 688) with videos related to

Sort By:
Pageof 69
Journal of Colloid and Interface Science|July 15, 2026
Myelin basic protein binding is modulated by leaflet asymmetry and lipid compositionJulio M Pusterla, Alexandros Koutsioubas, Nicolò Paracini, et al.
Annals of the Rheumatic Diseases|March 6, 2014
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitorArthur Kavanaugh, Philip J Mease, Juan J Gomez-Reino, et al.
Annals of Internal Medicine|September 13, 2013
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trialJoel Kremer, Zhan-Guo Li, Stephen Hall, et al.
The Journal of Rheumatology|March 4, 2014
Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trialMark C Genovese, César Pacheco Tena, Arturo Covarrubias, et al.
Annals of the Rheumatic Diseases|May 18, 2010
Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT groupJérôme Avouac, Otylia Kowal-Bielecka, David Pittrow, et al.
The Journal of Rheumatology|May 5, 2007
Outcome measures in psoriatic arthritisDafna D Gladman, Philip J Mease, Paul Healy, et al.
Arthritis Care & Research|October 17, 2015
Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical TrialPaul Emery, Roy M Fleischmann, Ingrid Strusberg, et al.
Clinical and Experimental Rheumatology|December 21, 2019
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan studyVibeke Strand, Désirée van der Heijde, Yoshiya Tanaka, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2019
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III StudyDésirée van der Heijde, Vibeke Strand, Yoshiya Tanaka, et al.
Arthritis Research & Therapy|June 25, 2011
Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are neededChristopher P Denton, Jerome Avouac, Frank Behrens, et al.
Pageof 69